Searchable abstracts of presentations at key conferences in endocrinology

ea0034p89 | Clinical practice/governance and case reports | SFEBES2014

Low dose tolvpatan (7.5 mg) is effective in the management of SIADH in oncology patients (results from a retrospective audit at The Christie Hospital and Wythenshawe Pulmonary Oncology Unit)

King Jennifer , Kyriacou Angelos , Issa Basil , Taylor Paul , Higham Claire

Tolvaptan (a selective V2 receptor antagonist) is licensed for the inpatient management of SIADH induced hyponatraemia, a common complication in patients with malignancy. Licensed daily doses start at 15 mg but there is evidence that some patients have a rise in serum sodium (Na) of >12 mmol/l per 24 h in response to this. Lower initial doses (7.5 mg) may therefore be appropriate1,2.Methods: A retrospective case note audit was performed. T...